FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024104290> ?p ?o ?g. }

• W2024104290 endingPage "115" @default.
• W2024104290 startingPage "108" @default.
• W2024104290 abstract "Phlegmasia cerulea dolens is a devastating complication of massive deep venous thrombosis, which is clinically characterized by massive lower extremity tissue edema and subsequent arterial insufficiency. These experiments evaluated the local tissue effects of acute global venous obstruction combined with partial arterial ischemia. Experiments were performed to assess the effects of heparin on the cytokine response to simultaneous venous and partial arterial obstruction. Murine hind limbs were subjected to conditions of unilateral venous occlusion and partial tourniquet limb ischemia, which was confirmed by laser Doppler imaging (LDI). Mice underwent either hind limb venous obstruction with intravenous unfractionated heparin (200 IU/kg) or intravenous saline 5 min before venous occlusion. Sham-treated mice were subjected to anesthesia alone without venous occlusion. After 3 hr, the mice were killed and tissue was harvested for measurement of edema (wet to dry weight ratio, W/D), muscle viability, indices of local thrombosis (thrombin-antithrombin complex [TAT]), and cytokine analysis for growth-related oncogene-1 (GRO-1) and interleukin-6 (IL-6, protein via enzyme-linked immunoassay and mRNA via reverse transcriptase polymerase chain reaction). Bleeding time and volume were documented in saline- and heparin-treated mice to confirm systemic anticoagulation. Administration of intravenous heparin resulted in a marked increase in bleeding time and volume. LDI confirmed venous obstruction and ongoing arterial inflow. Venous obstruction resulted in severe visible edema that correlated with a significantly higher W/D ratio but was not associated with a significant decrease in muscle viability. GRO-1 and IL-6 protein and mRNA levels were significantly elevated in the venous occlusion group compared to sham. Heparin therapy significantly decreased TAT3 levels but did not alter the profile of GRO-1 or IL-6 protein levels seen with venous occlusion. Venous occlusion with partial ischemia induces a unique and potent local cytokine expression. Heparin therapy did not ameliorate the cytokine response. These data indicate that heparin therapy does not modulate the cytokine response to venous obstruction. Phlegmasia cerulea dolens is a devastating complication of massive deep venous thrombosis, which is clinically characterized by massive lower extremity tissue edema and subsequent arterial insufficiency. These experiments evaluated the local tissue effects of acute global venous obstruction combined with partial arterial ischemia. Experiments were performed to assess the effects of heparin on the cytokine response to simultaneous venous and partial arterial obstruction. Murine hind limbs were subjected to conditions of unilateral venous occlusion and partial tourniquet limb ischemia, which was confirmed by laser Doppler imaging (LDI). Mice underwent either hind limb venous obstruction with intravenous unfractionated heparin (200 IU/kg) or intravenous saline 5 min before venous occlusion. Sham-treated mice were subjected to anesthesia alone without venous occlusion. After 3 hr, the mice were killed and tissue was harvested for measurement of edema (wet to dry weight ratio, W/D), muscle viability, indices of local thrombosis (thrombin-antithrombin complex [TAT]), and cytokine analysis for growth-related oncogene-1 (GRO-1) and interleukin-6 (IL-6, protein via enzyme-linked immunoassay and mRNA via reverse transcriptase polymerase chain reaction). Bleeding time and volume were documented in saline- and heparin-treated mice to confirm systemic anticoagulation. Administration of intravenous heparin resulted in a marked increase in bleeding time and volume. LDI confirmed venous obstruction and ongoing arterial inflow. Venous obstruction resulted in severe visible edema that correlated with a significantly higher W/D ratio but was not associated with a significant decrease in muscle viability. GRO-1 and IL-6 protein and mRNA levels were significantly elevated in the venous occlusion group compared to sham. Heparin therapy significantly decreased TAT3 levels but did not alter the profile of GRO-1 or IL-6 protein levels seen with venous occlusion. Venous occlusion with partial ischemia induces a unique and potent local cytokine expression. Heparin therapy did not ameliorate the cytokine response. These data indicate that heparin therapy does not modulate the cytokine response to venous obstruction." @default.
• W2024104290 created "2016-06-24" @default.
• W2024104290 creator A5012438754 @default.
• W2024104290 creator A5015655834 @default.
• W2024104290 creator A5034319347 @default.
• W2024104290 creator A5038514804 @default.
• W2024104290 creator A5073880360 @default.
• W2024104290 creator A5079628450 @default.
• W2024104290 creator A5090236875 @default.
• W2024104290 date "2009-01-01" @default.
• W2024104290 modified "2023-09-23" @default.
• W2024104290 title "Effects of Acute Global Venous Obstruction and Unfractionated Heparin on Muscle Cytokine Synthesis" @default.
• W2024104290 cites W1481234838 @default.
• W2024104290 cites W1499173185 @default.
• W2024104290 cites W1531522022 @default.
• W2024104290 cites W1960915004 @default.
• W2024104290 cites W1970880826 @default.
• W2024104290 cites W1971048949 @default.
• W2024104290 cites W1972206092 @default.
• W2024104290 cites W1985375939 @default.
• W2024104290 cites W1987147413 @default.
• W2024104290 cites W1994157173 @default.
• W2024104290 cites W2001185486 @default.
• W2024104290 cites W2008184120 @default.
• W2024104290 cites W2010660341 @default.
• W2024104290 cites W2058011287 @default.
• W2024104290 cites W2070919054 @default.
• W2024104290 cites W2071979411 @default.
• W2024104290 cites W2080722765 @default.
• W2024104290 cites W2081568584 @default.
• W2024104290 cites W2086840459 @default.
• W2024104290 cites W2087715514 @default.
• W2024104290 cites W2091500663 @default.
• W2024104290 cites W2092204468 @default.
• W2024104290 cites W2096668933 @default.
• W2024104290 cites W2099908568 @default.
• W2024104290 cites W2127259448 @default.
• W2024104290 cites W2127881387 @default.
• W2024104290 cites W2156644795 @default.
• W2024104290 cites W2164265355 @default.
• W2024104290 cites W2418071929 @default.
• W2024104290 cites W254641055 @default.
• W2024104290 cites W45940644 @default.
• W2024104290 cites W67249329 @default.
• W2024104290 cites W93880446 @default.
• W2024104290 cites W2754861703 @default.
• W2024104290 doi "https://doi.org/10.1016/j.avsg.2008.05.003" @default.
• W2024104290 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18640815" @default.
• W2024104290 hasPublicationYear "2009" @default.
• W2024104290 type Work @default.
• W2024104290 sameAs 2024104290 @default.
• W2024104290 citedByCount "1" @default.
• W2024104290 countsByYear W20241042902012 @default.
• W2024104290 crossrefType "journal-article" @default.
• W2024104290 hasAuthorship W2024104290A5012438754 @default.
• W2024104290 hasAuthorship W2024104290A5015655834 @default.
• W2024104290 hasAuthorship W2024104290A5034319347 @default.
• W2024104290 hasAuthorship W2024104290A5038514804 @default.
• W2024104290 hasAuthorship W2024104290A5073880360 @default.
• W2024104290 hasAuthorship W2024104290A5079628450 @default.
• W2024104290 hasAuthorship W2024104290A5090236875 @default.
• W2024104290 hasConcept C126322002 @default.
• W2024104290 hasConcept C141071460 @default.
• W2024104290 hasConcept C2777397205 @default.
• W2024104290 hasConcept C2777557582 @default.
• W2024104290 hasConcept C2780011451 @default.
• W2024104290 hasConcept C2780868729 @default.
• W2024104290 hasConcept C2780886150 @default.
• W2024104290 hasConcept C42219234 @default.
• W2024104290 hasConcept C541997718 @default.
• W2024104290 hasConcept C71924100 @default.
• W2024104290 hasConceptScore W2024104290C126322002 @default.
• W2024104290 hasConceptScore W2024104290C141071460 @default.
• W2024104290 hasConceptScore W2024104290C2777397205 @default.
• W2024104290 hasConceptScore W2024104290C2777557582 @default.
• W2024104290 hasConceptScore W2024104290C2780011451 @default.
• W2024104290 hasConceptScore W2024104290C2780868729 @default.
• W2024104290 hasConceptScore W2024104290C2780886150 @default.
• W2024104290 hasConceptScore W2024104290C42219234 @default.
• W2024104290 hasConceptScore W2024104290C541997718 @default.
• W2024104290 hasConceptScore W2024104290C71924100 @default.
• W2024104290 hasIssue "1" @default.
• W2024104290 hasLocation W20241042901 @default.
• W2024104290 hasLocation W20241042902 @default.
• W2024104290 hasOpenAccess W2024104290 @default.
• W2024104290 hasPrimaryLocation W20241042901 @default.
• W2024104290 hasRelatedWork W106713615 @default.
• W2024104290 hasRelatedWork W1988855938 @default.
• W2024104290 hasRelatedWork W1996292932 @default.
• W2024104290 hasRelatedWork W2128880450 @default.
• W2024104290 hasRelatedWork W2371372815 @default.
• W2024104290 hasRelatedWork W2376676163 @default.
• W2024104290 hasRelatedWork W2415978481 @default.
• W2024104290 hasRelatedWork W2801779377 @default.
• W2024104290 hasRelatedWork W4240572043 @default.
• W2024104290 hasRelatedWork W4254049786 @default.
• W2024104290 hasVolume "23" @default.
• W2024104290 isParatext "false" @default.

• next